

Licensing as Exit Strategy for EIC beneficiaries

EIC European Innovation Council (EISMEA)

Xana Belastegui Partner 24/01/23






Agri Food value chain

Aspects impacting license strategy



BUSINESS STRATEGY AND GOALS



1. Gene trait license

Plant gene trait to increase crop quality Startup to Seed Corporate

Stage

Trait validated in 4 crops

IΡ

Internationa

Mostly granted

Not directly owned by startup

AGREEMENT

Co-development + commercial license; NA; 1 crop


IP: cost assumed by the startup

New IP: shared

Revenue model

- ✓ Upfront payment (100K)
- ✓ Co-development activities as service (60K)
- ✓ Per milestones achievement: 1st validation field trial, 1st regulatory field trial, 1st commercial sale
- ✓ Royalties: 10% of net trait value







3. Microbial strain for use in agriculture



Bacterial strain to produce biostimulants for agriculture

Start up to Agrochemical corporate

Field validation Lab scale production

Stage

IP
International
Not granted yet
Owned by startup

AGREEMENT

License for development and commercialization; NA and LATAM; all crops

IP: cost assumed by the startup

New IP: shared/corporate

Revenue model

- ✓ Upfront payment (30K)
- ✓ Per milestones achievement: field regulatory approval, 1st commercial sale; net annual sales higher than X amount
- √ Royalties scheme 3% (minimum royalties payment agreed)

Some take aways



Knowhow/IP

What are you licensing out/in?

Knowhow, technology, actives, product, material....

What for and where?

Level of control before and after?



Which risks are you assuming?

Who owns what?

Who pays what?

Breach/Termination



Agreement

Different ways and models for licensing

Opportunity for collaboration and learning

Win-Win mindset



Thanks!

xana@dnaadvisory.net